CA2315265A1 - Allongement de la duree de vie d'une cellule, et procedes et reactifs associes - Google Patents

Allongement de la duree de vie d'une cellule, et procedes et reactifs associes Download PDF

Info

Publication number
CA2315265A1
CA2315265A1 CA002315265A CA2315265A CA2315265A1 CA 2315265 A1 CA2315265 A1 CA 2315265A1 CA 002315265 A CA002315265 A CA 002315265A CA 2315265 A CA2315265 A CA 2315265A CA 2315265 A1 CA2315265 A1 CA 2315265A1
Authority
CA
Canada
Prior art keywords
cell
cells
telomerase
agent
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315265A
Other languages
English (en)
Inventor
Gregory J. Hannon
Jing Wang
David H. Beach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2315265A1 publication Critical patent/CA2315265A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur un procédé et des réactifs permettant d'allonger la durée de vie, c.-à-d. le nombre des divisions mitotiques, d'une cellule. Ledit procédé, qui se base d'une manière générale sur l'expression ectopique de la sous-unité catalytique EST2 de la télomérase ou d'un de ses fragments bioactifs, peut s'utiliser in vivo, ex vivo et in situ.
CA002315265A 1998-01-12 1999-01-12 Allongement de la duree de vie d'une cellule, et procedes et reactifs associes Abandoned CA2315265A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7122098P 1998-01-12 1998-01-12
US60/071,220 1998-01-12
US7145598P 1998-01-13 1998-01-13
US60/071,455 1998-01-13
US6365798A 1998-04-21 1998-04-21
US09/063,657 1998-04-21
PCT/US1999/000682 WO1999035243A2 (fr) 1998-01-12 1999-01-12 Allongement de la duree de vie d'une cellule, et procedes et reactifs associes

Publications (1)

Publication Number Publication Date
CA2315265A1 true CA2315265A1 (fr) 1999-07-15

Family

ID=27370514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315265A Abandoned CA2315265A1 (fr) 1998-01-12 1999-01-12 Allongement de la duree de vie d'une cellule, et procedes et reactifs associes

Country Status (6)

Country Link
EP (1) EP1045697A2 (fr)
JP (1) JP2002500040A (fr)
AU (1) AU759437B2 (fr)
CA (1) CA2315265A1 (fr)
IL (1) IL137101A0 (fr)
WO (1) WO1999035243A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572845B2 (en) * 1998-10-16 2003-06-03 Burt D. Ensley Recombinant hair treatment compositions
CA2352486A1 (fr) * 1998-11-25 2000-06-02 Genetica, Inc. Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
AU2006202072B2 (en) * 1999-08-05 2010-12-09 Abt Holding Company Multipotent adult stem cells and methods for isolation
IL147990A0 (en) * 1999-08-05 2002-09-12 Mcl Llc Multipotent adult stem cells and methods for isolation
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1103615A1 (fr) * 1999-11-25 2001-05-30 Universite De Geneve Vecteurs capables d'immortaliser les cellules ne se divisant pas et les cellules immortalisées par ces vecteurs
FR2810046B1 (fr) * 2000-06-07 2004-09-10 Neurotech Procede d'immortalisation conditionnelle de cellules et les constructions proteiques pour sa mise en oeuvre
US20020045219A1 (en) * 2000-08-02 2002-04-18 Whitehead Institute For Biomedical Research Production of human monoclonal antibodies
US6686159B2 (en) 2000-08-24 2004-02-03 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
IL157332A0 (en) 2001-02-14 2004-02-19 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AU2002345743A1 (en) 2001-06-21 2003-01-08 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same
EP1472340A4 (fr) * 2002-02-05 2006-11-08 Rappaport Family Inst For Res Cellules souches determinees pour une lignee selectionnees pour l'activite du promoteur de la telomerase
WO2004050859A2 (fr) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Recombinaison homologue dans des cellules souches adultes multipotentes
PL2548880T3 (pl) 2003-06-23 2019-07-31 Telomerase Activation Sciences, Inc. Kompozycje powodujące wzrost aktywności telomerazy
WO2005000248A2 (fr) 2003-06-25 2005-01-06 Geron Corporation Compositions et procedes de traitement de la peau
US8426200B2 (en) 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
JP2009511061A (ja) 2005-10-14 2009-03-19 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 膵臓表現型を有する細胞への非胚性幹細胞の分化
EP2087101A2 (fr) 2006-11-24 2009-08-12 Regents of the University of Minnesota Cellules progénitrices endothermiques
WO2009092092A1 (fr) 2008-01-18 2009-07-23 Regents Of The University Of Minnesota Agrégats de cellules souches et procédés de préparation et d'utilisation
EP2362899A1 (fr) 2008-10-31 2011-09-07 Katholieke Universiteit Leuven Procédés optimisés pour la différenciation de cellules en cellules présentant des phénotypes d'hépatocytes et de cellules souches d'hépatocytes, cellules produites par ces procédés et procédés pour l'utilisation des cellules
KR102265757B1 (ko) 2009-03-09 2021-06-17 바이오아트라, 인코퍼레이티드 미락 단백질
CN104447936A (zh) 2009-05-18 2015-03-25 Ta科学公司(美国) 用于增加端粒酶活性的组合物和方法
DK2536830T3 (da) 2010-02-16 2019-10-21 Ultimovacs As Polypeptider
DK2568991T6 (en) 2010-05-12 2019-03-18 Abt Holding Co MODULATION OF SPLENOCYTES IN CELL THERAPY
WO2011158125A2 (fr) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Procédé de différenciation de cellules en cellules étoilées du foie et en cellules endothéliales sinusoïdales du foie, cellules produites par ces procédés, et procédés d'utilisation des cellules
ES2590461T3 (es) * 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
SG10201506664TA (en) 2010-08-24 2015-10-29 Univ Minnesota Non-static suspension culture of cell aggregates
HUE052516T2 (hu) 2013-04-12 2021-05-28 Houston Methodist Hospital Szervek javítása transzplantációhoz
CN114657281A (zh) * 2020-12-22 2022-06-24 中国科学院动物研究所 内源病毒作为衰老程度的标志物及其作为衰老干预靶标的应用
CN114601747A (zh) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 一种催生蛋白及rna具有延长细胞端粒和增殖的核蛋白端粒酶在化妆品中的应用
WO2024075819A1 (fr) * 2022-10-07 2024-04-11 Ａｇｃ株式会社 Procédé de production de vecteur viral utilisant une cellule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830644A (en) * 1992-05-13 1998-11-03 Geron Corporation Method for screening for agents which increase telomerase activity in a cell
WO1995013382A1 (fr) * 1993-11-12 1995-05-18 Geron Corporation Diagnostic et traitement de desordres lies a la longueur de telomeres et/ou l'activite de la telomerase
EP0832190A1 (fr) * 1995-06-07 1998-04-01 Cold Spring Harbor Laboratory Oligonucleotides essentiels de la telomerase de vertebre

Also Published As

Publication number Publication date
AU2317299A (en) 1999-07-26
IL137101A0 (en) 2001-06-14
WO1999035243A9 (fr) 1999-10-28
WO1999035243A3 (fr) 1999-09-16
WO1999035243A2 (fr) 1999-07-15
EP1045697A2 (fr) 2000-10-25
JP2002500040A (ja) 2002-01-08
AU759437B2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
AU759437B2 (en) Extension of cellular lifespan, methods and reagents
CA2352486A1 (fr) Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative
AU2001264598B2 (en) Compositions and methods for tissue dedifferentiation and regeneration
US5958769A (en) Compositions and methods for mediating cell cycle progression
US5854067A (en) Hexokinase inhibitors
AP1011A (en) Defective recombinant virus and its use for treating hyperproliferative disorders, in particular restenosis.
AU2001264598A1 (en) Compositions and methods for tissue dedifferentiation and regeneration
AU2003300794A1 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
HUE034558T2 (en) Method for Cellular RNA Expression
EP0998307B1 (fr) TRAITEMENT DES MALADIES VASCULAIRES PROLIFERATIVES A L'AIDE DE p27 ET DE SES PROTEINES HYBRIDES
US5891717A (en) Methods and compositions for inhibiting hexokinase
AU2016264166A1 (en) Method for inducing oligodendrocyte precursor cells from Oct4-induced human somatic cells through direct reprogramming
US20090036393A1 (en) Vesicular monoamine transporter gene therapy in Parkinson's disease
US20200368284A1 (en) Angiopoietin-1- or vegf-secreting stem cell and pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising same
US7732206B2 (en) Oligodendrocyte determination genes and uses thereof
AU760252B2 (en) Modulation of cell proliferation, methods and reagents
EP0792366A1 (fr) Therapie genique enzymatique catalysant la conversion extracellulaire d'un precurseur
KR102414138B1 (ko) Wnt 단백질 활성 증진용 배지 조성물
CA2236332A1 (fr) Traitement du diabete a l'aide d'un gene de glucokinase
US20200289575A1 (en) Pharmaceutical composition for preventing or treating neurological disorders or cardiovascular diseases, comprising srage-secreting stem cell
WO2001048149A1 (fr) Cellule de moelle osseuse adulte capable de se differencier en cellule de muscle cardiaque
DiGirolamo The potential of human bone marrow stromal cells as vehicles for ex vivo gene therapy applications
TW201139675A (en) NeuroD1 gene expression in non-endocrine pancreatic epithelial cells (NEPECs)

Legal Events

Date Code Title Description
FZDE Discontinued